Compare Atomera Incorporated (ATOM) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atomera Incorporated vs Twist Bioscience Corp — how do they compare? Atomera Incorporated trades at $6.48 (market cap $247.40M), while Twist Bioscience Corp trades at $92.62 (market cap $5.77B). The key difference: Twist Bioscience Corp is far larger — about 23.3× Atomera Incorporated's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Atomera Incorporated nearer its low. Which is the better fit depends on your goals.
| ATOM | TWST | |
|---|---|---|
Market Cap | $247.40M | $5.77B |
Sector | Technology | Health |
52-Week High | $12.11 | $102.88 |
52-Week Low | $1.99 | $24.16 |
Enterprise Value | $207.61M | $5.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ATOM trades at $6.25, down 5.73% over 24 hours, reflecting a bearish technical outlook with negative earnings trends. The company reported a net loss of $20.17 million in 2025 on minimal revenue of $65,000, with profitability metrics deeply negative. Recent news highlights Atomera's focus on semiconductor technology advancements, including GaN-on-Silicon collaborations, but financial performance remains a significant concern.
The outlook is cautious due to persistent losses and weak revenue, though analyst consensus is unanimously bullish with a 100% buy rating. Key risks include execution challenges in monetizing technology and high cash burn. Upside depends on successful commercialization of its semiconductor IP, but current fundamentals suggest high volatility and substantial shareholder risk.
TWST trades at $90.35, down 0.31% on the day, with a bullish technical signal supported by moving averages and oversold RSI levels near key support at $89. Revenue growth remains strong, reaching $376.57M in 2025, though the company continues to report net losses. Recent news highlights AI-driven drug discovery collaborations and insider selling activity, while analyst consensus leans bullish with a $91.63 price target.
The stock offers growth exposure to synthetic biology and AI-enabled therapeutics, but carries significant risk due to persistent negative cash flow and profitability challenges. Investor sentiment is cautiously optimistic, balancing innovation potential against financial sustainability concerns in a competitive biotech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Atomera Incorporated
Atomera is a semiconductor materials engineering company. Its Mears Silicon Technology (MST) is a patented thin film that enhances transistor performance, power efficiency, and cost for global chip manufacturers.
Read more on ATOM →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
